Article
Medicine, General & Internal
Michael Gnant, Florian Fitzal, Gabriel Rinnerthaler, Guenther G. Steger, Sigrun Greil-Ressler, Marija Balic, Dietmar Heck, Raimund Jakesz, Josef Thaler, Daniel Egle, Diether Manfreda, Vesna Bjelic-Radisic, Ursula Wieder, Christian F. Singer, Elisabeth Melbinger-Zeinitzer, Ferdinand Haslbauer, Paul Sevelda, Harald Trapl, Viktor Wette, Kerstin Wimmer, Simon P. Gampenrieder, Rupert Bartsch, Stephanie Kacerovsky-Strobl, Christoph Suppan, Christine Brunner, Christine Deutschmann, Lidija Soelkner, Christian Fesl, Richard Greil
Summary: This study showed that extending hormone therapy by 5 years in postmenopausal women with hormone-receptor-positive breast cancer who had received 5 years of adjuvant endocrine therapy provided no benefit over a 2-year extension but was associated with a greater risk of bone fracture.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Oncology
Lucia Del Mastro, Mauro Mansutti, Giancarlo Bisagni, Riccardo Ponzone, Antonio Durando, Laura Amaducci, Enrico Campadelli, Francesco Cognetti, Antonio Frassoldati, Andrea Michelotti, Silvia Mura, Ylenia Urracci, Giovanni Sanna, Stefania Gori, Sabino De Placido, Ornella Garrone, Alessandra Fabi, Carla Barone, Stefano Tamberi, Claudia Bighin, Fabio Puglisi, Gabriella Moretti, Grazia Arpino, Alberto Ballestrero, Francesca Poggio, Matteo Lambertini, Filippo Montemurro, Paolo Bruzzi
Summary: The study showed that extending letrozole treatment to 5 years in postmenopausal patients with breast cancer who had received 2-3 years of tamoxifen resulted in a significant improvement in disease-free survival compared to the standard 2-3 years of letrozole treatment.
Article
Oncology
Steven Davies, Ioannis A. Voutsadakis
Summary: This study found that adjuvant chemotherapy is associated with better adherence to hormonal therapy in early ER-positive breast cancer patients, while patients with psychiatric co-morbidities are more likely to be non-adherent to hormonal therapy.
EUROPEAN JOURNAL OF CANCER CARE
(2022)
Article
Oncology
Tao He, Xu Li, Jiayuan Li, Zhu Wang, Yuan Fan, Xiusong Li, Zhoukai Fu, Yunhao Wu, Qing Lv, Ting Luo, Xiaorong Zhong, Jie Chen
Summary: This study investigated the changes in serum lipids during endocrine therapy for breast cancer patients. The results showed that TAM treatment significantly reduced LDL and TC levels in premenopausal patients. There were no adverse effects on lipid profiles in postmenopausal patients treated with AIs, and TAM had limited beneficial effects on serum lipids.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Xuanzi Qin, Peter Huckfeldt, Jean Abraham, Douglas Yee, Beth A. Virnig
Summary: Generic entry of aromatase inhibitors (AIs) allows for increased switching, which leads to improved adherence and better management of treatment-related side effects. However, patients and physicians may lack understanding of Part D benefit design, highlighting the need for improved education and communication to enhance decision-making.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2022)
Review
Oncology
Inga Bekes, Jens Huober
Summary: Seventy percent of breast cancer subtypes are hormone receptor-positive, and adjuvant endocrine therapy is crucial for these patients. Extending adjuvant endocrine therapy beyond 5 years has been shown to reduce the risk of late recurrence, but the optimal duration is still debated. Newer data suggest only marginal benefits beyond 7 to 10 years, and longer duration may result in more side effects. Therefore, it is important to select patients who qualify for extended therapy based on genomic tests and risk assessment.
Editorial Material
Oncology
Takahiko Kawate, Atsushi Yoshida, Sadatoshi Sugae, Souta Asaga, Hiroshi Kaise, Shigehira Saji, Chikako Yamauchi, Yasuo Miyoshi, Hideko Yamauchi, Takashi Ishikawa
Summary: The COVID-19 pandemic has had a major impact on Japan, leading medical institutions to take measures to minimize infection risks. Cancer treatment remains a priority, even during the epidemic, due to concerns about decreasing curability.
Article
Oncology
Yasemin Uslu, Vildan Kocatepe, Derya Subasi Sezgin, Cihan Uras
Summary: The purpose of this study was to investigate adjuvant tamoxifen adherence and associated factors in breast cancer survivors. The results showed that overall, breast cancer survivors in the study had moderate adherence to tamoxifen. Individual characteristics and treatment-related adverse effects influenced medication adherence. Healthcare professionals can increase adherence to this treatment by explaining its importance, addressing barriers to adherence, and providing evidence-based interventions.
SUPPORTIVE CARE IN CANCER
(2023)
Review
Oncology
Kathryn Hawrot, Lawrence N. Shulman, Ira J. Bleiweiss, Elizabeth J. Wilkie, Zachary A. K. Frosch, Rachel C. Jankowitz, Amy Laughlin
Summary: The study retrospectively analyzed the impact of COVID-19 on newly diagnosed breast cancer patients in 2020, finding a decrease in patient volume, no delays in treatment initiation, and a shift in initial treatment modality.
JCO ONCOLOGY PRACTICE
(2021)
Article
Oncology
Kathryn R. Tringale, Elizabeth R. Berger, Varadan Sevilimedu, Hannah Y. Wen, Erin F. Gillespie, Boris A. Mueller, Beryl McCormick, Amy J. Xu, John J. Cuaron, Oren Cahlon, Atif J. Khan, Simon N. Powell, Monica Morrow, Alexandra S. Heerdt, Lior Z. Braunstein
Summary: In this study, it was found that for older women with early-stage ER+/HER2- breast cancer, adjuvant RT and HT monotherapy both reduce the risk of locoregional recurrence, with a slightly better outcome for the combination therapy. Distant recurrence and breast cancer-specific survival rates did not significantly differ between the treatment groups. Further research is needed to determine the optimal treatment approach for these patients.
Article
Oncology
Takuji Iwase, Shigehira Saji, Kotaro Iijima, Kenji Higaki, Shoichiro Ohtani, Yasuyuki Sato, Yasuo Hozumi, Yoshie Hasegawa, Yasuhiro Yanagita, Hiroyuki Takei, Maki Tanaka, Hideji Masuoka, Masahiko Tanabe, Chiyomi Egawa, Yoshifumi Komoike, Toshitaka Nakamura, Hiroshi Ohtsu, Hirofumi Mukai
Summary: This study investigated the effects of extending the treatment with an aromatase inhibitor for 10 years on disease-free survival in postmenopausal hormone receptor-positive breast cancer patients. The results showed that extending the treatment with an aromatase inhibitor for an additional 5 years improved disease-free survival.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
John M. S. Bartlett, Dennis C. Sgroi, Kai Treuner, Yi Zhang, Tammy Piper, Ranelle C. Salunga, Ikhlaaq Ahmed, Lucy Doos, Sarah Thornber, Karen J. Taylor, Elena F. Brachtel, Sarah J. Pirrie, Catherine A. Schnabel, Daniel W. Rea
Summary: The study found that BCI (H/I) can significantly predict the benefit of extended tamoxifen therapy in HR+ N+ HER2(-) early-stage breast cancer patients. Moreover, BCI (H/I) demonstrates significant treatment to biomarker interaction across survival outcomes.
CLINICAL CANCER RESEARCH
(2022)
Review
Oncology
Melanie Kirkby, Alyanna M. Popatia, Jessie R. Lavoie, Lisheng Wang
Summary: The presence of estrogen receptor beta, the androgen receptor, and the glucocorticoid receptor on triple-negative breast cancer cells has presented new opportunities for treatment. This review explores the role of these receptors in the progression of triple-negative breast cancer and provides an overview of clinical trials targeting these receptors.
Article
Surgery
Andrew W. W. Hollins, Rachel E. E. Hein, Andrew N. N. Atia, Gloria X. X. Zhang, Amanda R. R. Sergesketter, Grant Darner, Miranda Morris, Suhail K. K. Mithani
Summary: The use of aromatase inhibitors (AIs) is associated with an increased incidence of trigger finger, especially in patients taking letrozole and anastrozole. Patients who require switching of medication regimens have a higher failure rate of steroid injection treatment. Poorly controlled diabetes and high hemoglobin A1c level are also independent factors for compromised steroid treatment of trigger finger.
PLASTIC AND RECONSTRUCTIVE SURGERY
(2023)
Article
Surgery
Maximilian Mahrhofer, Raphael Reichert, Laura Cosima Siegwart, Elisabeth Russe, Thomas Schoeller, Gottfried Wechselberger, Laurenz Weitgasser
Summary: This study aimed to evaluate the risk of perioperative hormone therapy in microsurgical breast reconstruction. It found that there is a certain association between perioperative hormone therapy and the risk of complications in microvascular flaps.
JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY
(2023)
Article
Gastroenterology & Hepatology
Raghav Sundar, Nesaretnam Barr Kumarakulasinghe, Yiong Huak Chan, Kazuhiro Yoshida, Takaki Yoshikawa, Yohei Miyagi, Yasushi Rino, Munetaka Masuda, Jia Guan, Junichi Sakamoto, Shiro Tanaka, Angie Lay-Keng Tan, Michal Marek Hoppe, Anand D. Jeyasekharan, Cedric Chuan Young Ng, Mark De Simone, Heike Grabsch, Jeeyun Lee, Takashi Oshima, Akira Tsuburaya, Patrick Tan
Summary: In the SAMIT trial, a gene signature predicting survival benefit from paclitaxel chemotherapy in gastric cancer patients was identified using machine-learning techniques. Patients were divided into Pac-Sensitive and Pac-Resistant groups, with Pac-Sensitive patients showing significant improvement in disease-free survival. This gene signature was validated in an external cohort, providing the first predictive biomarker for paclitaxel benefit in gastric cancer patients.
Article
Endocrinology & Metabolism
Akira Taguchi, Yukari Uemura, Shiro Tanaka, Hiroaki Ohta, Satoshi Mori, Hiroshi Hagino, Masataka Shiraki, Toshitaka Nakamura, Satoshi Soen
Summary: This study found that postmenopausal Japanese women with symptomatic periodontal disease had a significantly smaller increase in total hip bone density compared to those without periodontal disease during medication therapy for osteoporosis. Interventions to treat symptomatic periodontal disease before and/or during osteoporosis therapy could help maintain the effectiveness of osteoporosis medications.
ARCHIVES OF OSTEOPOROSIS
(2022)
Article
Medicine, General & Internal
Takayuki Ueno, Shigehisa Kitano, Norikazu Masuda, Daiki Ikarashi, Makiko Yamashita, Tomohiro Chiba, Takayuki Kadoya, Hiroko Bando, Takashi Yamanaka, Shoichiro Ohtani, Shigenori Nagai, Takahiro Nakayama, Masato Takahashi, Shigehira Saji, Kenjiro Aogi, Ravi Velaga, Kosuke Kawaguchi, Satoshi Morita, Hironori Haga, Shinji Ohno, Masakazu Toi
Summary: This study found that the density of CD4+ T cells in both the tumor and stromal regions is an independent predictor of pathological complete response (pCR) in patients with triple-negative breast cancer (TNBC). This predictive value is particularly strong in patients receiving platinum-containing chemotherapy.
Article
Oncology
Norihiro Shimoike, Tatsuto Nishigori, Yoshito Yamashita, Masato Kondo, Dai Manaka, Yoshio Kadokawa, Atsushi Itami, Seiichiro Kanaya, Hisahiro Hosogi, Seiji Satoh, Hiroaki Hata, Takatsugu Kan, Hironori Kawada, Michihiro Yamamoto, Eiji Tanaka, Shigeru Tsunoda, Shigeo Hisamori, Koya Hida, Kentaro Ueno, Shiro Tanaka, Kazutaka Obama
Summary: The study evaluated the safety of robotic gastrectomy in daily clinical practice and assessed the learning process in surgeons introduced to robotic procedures. Results showed that robotic gastrectomy was safely performed in actual clinical settings, although initial cases had longer operative time and promoted greater levels of surgeon fatigue compared to subsequent cases.
Letter
Endocrinology & Metabolism
Yasuhiro Matsubayashi, Alkihiro Yoshida, Hideki Suganami, Momoko Oe, Takaaki Sato, Yuta Yaguchi, Kazuya Fujihara, Takaho Yamada, Shiro Tanaka, Kohei Kaku, Hirohito Sone
DIABETES OBESITY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Satoshi Mori, Hiroshi Hagino, Toshitsugu Sugimoto, Shiro Tanaka, Yuji Mitomo, Kaito Takahashi, Teruki Sone, Toshitaka Nakamura, Satoshi Soen
Summary: This study aimed to determine whether sequential therapy with teriparatide, followed by alendronate, is more effective in preventing fractures compared to monotherapy with alendronate. The results showed that in women with osteoporosis at high risk of fracture, once-weekly teriparatide injection followed by alendronate significantly reduced the incidence of morphometric vertebral fractures compared to alendronate monotherapy.
OSTEOPOROSIS INTERNATIONAL
(2023)
Meeting Abstract
Hematology
Hiroyuki Takahashi, Shiro Tanaka, Yuki Yuza, Yuka Iijima-Yamashita, Daisuke Hasegawa, Hiroshi Moritake, Kiminori Terui, Shotaro Iwamoto, Akira Shimada, Jun Matsubayashi, Takao Deguchi, Yoshiko Hashii, Nobutaka Kiyokawa, Hayato Miyachi, Akiko Moriya Saito, Takashi Taga, Souichi Adachi, Daisuke Tomizawa
Meeting Abstract
Hematology
Daisuke Tomizawa, Shiro Tanaka, Shotaro Iwamoto, Hidefumi Hiramatsu, Jun Matsubayashi, Daisuke Hasegawa, Hiroshi Moritake, Daiichiro Hasegawa, Kiminori Terui, Asahito Hama, Shin-ichi Tsujimoto, Nobutaka Kiyokawa, Hayato Miyachi, Takao Deguchi, Yoshiko Hashii, Yuka Iijima-Yamashita, Tomohiko Taki, Yasushi Noguchi, Kazutoshi Koike, Katsuyoshi Koh, Yuki Yuza, Akiko Moriya Saito, Keizo Horibe, Takashi Taga, Souichi Adachi
Article
Oncology
Masaya Hattori, Norikazu Masuda, Toshimi Takano, Koichiro Tsugawa, Kenichi Inoue, Koji Matsumoto, Takashi Ishikawa, Mitsuya Itoh, Hiroyuki Yasojima, Yuko Tanabe, Keiko Yamamoto, Masato Suzuki, Wilbur Pan, Javier Cortes, Hiroji Iwata
Summary: In the KEYNOTE-355 trial, pembrolizumab plus chemotherapy showed improved progression-free survival (PFS) and overall survival (OS) compared to placebo plus chemotherapy in previously untreated patients with locally recurrent inoperable or metastatic triple-negative breast cancer. The study included Japanese patients, and the results were consistent with the global population. The combination of pembrolizumab and chemotherapy demonstrated manageable toxicity and supported its use in this setting.
Article
Public, Environmental & Occupational Health
Hisashi Noma, Munechika Misumi, Shiro Tanaka
Summary: Ordinary logistic regression analyses are widely used in case-cohort studies, but their odds ratio estimates cannot be interpreted as relative risk measures unless the event rate is low. This study introduces pseudo-Poisson and pseudo-normal linear regression methods that can estimate risk ratios and risk differences. By using weighting and auxiliary variable information, these estimators provide accurate and precise results. These alternative approaches are recommended for case-cohort studies, especially when the event rate is not low.
JOURNAL OF EPIDEMIOLOGY
(2023)
Article
Oncology
Toshimi Takano, Mitsuya Ito, Takayuki Kadoya, Tomofumi Osako, Tomoyuki Aruga, Norikazu Masuda, Toshiko Miyaki, Naoki Niikura, Daisuke Shimizu, Yuichi Yokoyama, Manabu Watanabe, Masato Tomomitsu, Kenjiro Aogi
Summary: This study investigated the efficacy and safety of MD-110 in early-stage breast cancer patients receiving neoadjuvant or adjuvant myelosuppressive chemotherapy. The results showed that MD-110 was effective in reducing chemotherapy-induced neutropenia without additional safety concerns.
Article
Oncology
Misato Masuyama, Norikazu Masuda, Hidetoshi Kawaguchi, Yutaka Yamamoto, Shigehira Saji, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Shoichiro Ohtani, Nobuaki Sato, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Toshinari Yamashita, Daisuke Yotsumoto, Masakazu Toi, Shinji Ohno
Summary: The role of endocrine therapy in postmenopausal patients with ER-positive HER2-positive AMBC is unclear. The Safari study analyzed data from 94 patients and found that F500 therapy as first- or second-line treatment resulted in longer TTF. Furthermore, patients with TTC ≥ 3 years had prolonged OS, suggesting that this value could be used as a cut-off for predicting clinical outcomes.
Article
Endocrinology & Metabolism
Hiroaki Ohta, Yukari Uemura, Teruki Sone, Shiro Tanaka, Satoshi Soen, Satoshi Mori, Hiroshi Hagino, Masao Fukunaga, Toshitaka Nakamura, Hajime Orimo, Masataka Shiraki
Summary: The positive link between osteoporosis and hypercholesterolemia has been acknowledged, and bone resorption inhibitors, such as nitrogen-containing bisphosphonates (N-BP) and selective estrogen receptor modulators (SERMs), have been found to lower serum cholesterol levels. However, the association between baseline cholesterol level and incident fracture rate under treatment with these inhibitors has not been studied. This research investigated the relationship between vertebral fracture incidents and baseline cholesterol levels, as well as the cholesterol-lowering effects of N-BP and SERM in osteoporosis patients.
CALCIFIED TISSUE INTERNATIONAL
(2023)
Article
Endocrinology & Metabolism
Shiro Tanaka, Mitsuru Saito, Hiroshi Hagino, Satoshi Mori, Toshitaka Nakamura, Hiroaki Ohta, Teruki Sone, Kaito Takahashi, Yuji Mitomo, Toshitsugu Sugimoto, Satoshi Soen
Summary: This study investigated the association between urinary pentosidine level and the risk of fracture in patients with severe osteoporosis. The results showed that urinary pentosidine level was associated with the incidence of vertebral and nonvertebral fractures, with the strongest association observed for nonvertebral fractures.
Article
Oncology
Daisuke Tomizawa, Shin-ichi Tsujimoto, Shiro Tanaka, Jun Matsubayashi, Takahiro Aoki, Shotaro Iwamoto, Daisuke Hasegawa, Kozo Nagai, Kentaro Nakashima, Koji Kawaguchi, Takao Deguchi, Nobutaka Kiyokawa, Kentaro Ohki, Hidefumi Hiramatsu, Norio Shiba, Kiminori Terui, Akiko Moriya Saito, Motohiro Kato, Takashi Taga, Tsugumichi Koshinaga, Souichi Adachi
Summary: This study aims to establish an appropriate treatment for children with de novo acute myeloid leukemia, based on recurrent leukemic cytogenetic abnormalities and flow-cytometric minimal residual disease. It also aims to validate the safety and efficacy of gemtuzumab ozogamicin combined with post-induction chemotherapy for non-low-risk patients.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2022)